Leveraging novel chemistry to inhibit previously undruggable DUB targets

Attracting both investors and big pharma, Mission Therapeutics is targeting a range of unmet medical needs, including Parkinson’s disease, with its unique deubiquitylating enzyme (DUB) platform.

Go to the profile of Mission Therapeutics
Nov 01, 2017
1
0
Page of
Go to the profile of Mission Therapeutics

Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, fibrosis, inflammation, cancer and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis. The Company has raised $125M from investors Imperial Innovations, Pfizer Venture Investments, Roche Venture Fund, Sofinnova Partners, SR One and Woodford Patient Capital Trust. Mission is based at the Babraham Research Campus, Cambridge, UK.

No comments yet.